Sales enablement for Series A companies: the 90-day install for healthcare and life sciences in the Benelux region
The exact 90-day plan for standing up sales enablement at Series A — the point where the founder can no longer be every function. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Benelux region.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Benelux region. In this market, Benelux buyers reward multilingual specificity and a pitch that respects local nuance, so the way you install sales enablement has to be shaped to that reality from day one.
Series A is the moment sales enablement stops being optional. The founder has to step out of some of the work, the plan requires a defensible growth number, and every quarter compounds toward the next raise.
Day 1 to 30: diagnosis and instrumentation. Name the constraint, write the ICP, wire ramp time for new reps to first closed-won into the board pack.
Day 31 to 60: first live cycle at 20% of planned volume. Founder still in every review. Kill criteria written and enforced.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Benelux region it is compounded by the fact that local nuance and language fit, not scale is what actually gates growth. Sales enablement is only useful here when it is pointed at both constraints at once.
Day 61 to 90: ramp to full volume, hire the first dedicated operator, and hand off ops. Founder retains strategy and the weekly review.
By day 90 the metric is legible and the trajectory is defensible. This is what turns a Series A story into a Series B round.
Trap most Series A companies fall into: content libraries no one opens. It usually shows up around day 45 when the founder tries to hire ahead of the model.
The Series A version of sales enablement looks small compared to what you will build at Series B. That is the point — it is a foundation, not a monument.
Concretely for healthcare and life sciences in the Benelux region: the healthcare teams that install this get past procurement instead of dying in it, and one anchored Benelux customer becomes the reference the rest of the region asks for. That is the reason it is worth installing sales enablement deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Sales · healthcare · Benelux — answered
- Does sales enablement work for healthcare and life sciences in the Benelux region?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Benelux region, Benelux buyers reward multilingual specificity and a pitch that respects local nuance. The healthcare teams that install this get past procurement instead of dying in it.
- Should we start sales enablement before Series A?
- Yes if the founder has time; the Series A version is the same model at higher spend.
- How much of the round should fund sales enablement?
- Meaningful — often 20–30% of the growth line — but only after diagnosis.
- When do we hire the first sales enablement operator?
- Around day 60, once the model has run one full cycle with the founder.
- What Series A trap should we avoid?
- Content libraries no one opens — usually a premature senior hire.
- What is the Benelux-specific pitfall when running sales enablement for healthcare?
- Importing a playbook that was built for another market. In the Benelux region, Benelux buyers reward multilingual specificity and a pitch that respects local nuance — the install has to reflect that.
Growth Broker editorial
Filed under sales · healthcare · benelux